In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

AC Immune SA cofounder and CEO Andrea Pfeifer offers lessons in strategy and resilience for building and maintaining a drug ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a ...

To unlock value and avoid costly mistakes, life sciences BD teams must work with commercial teams to help evaluate potential ...

Life sciences companies face an impending “tax policy trifecta” including potential TCJA expiration, U.S. trade and regulatory overhaul, and implementation of the OECD’s global minimum tax regime.